Product image of Gluco-Pet (Fludeoxyglucose (18f)) supplied by GNH India

Gluco-Pet

Active Ingredient:
Fludeoxyglucose (18f)
Origin:
EU

Gluco-Pet (Fludeoxyglucose (18f))

Gluco-Pet is an injectable solution containing the radiopharmaceutical fludeoxyglucose (18F). It is supplied in a sterile vial for intravenous administration and is used primarily in the European market for diagnostic imaging. The compound acts as a glucose analog that accumulates in metabolically active cells, enabling positron emission tomography (PET) to visualize tissue function. It is a prescription‑only product with no established strength or dosage listed.

Manufacturer / TM Owner

University Of Debrecen Medical Center Nuclear Medicine

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Gluco-Pet is indicated for several PET imaging applications that assess metabolic activity in different organ systems.

  • Oncologic PET imaging to detect, stage, and monitor malignant tumors.
  • Cardiac PET perfusion studies for evaluation of myocardial viability and ischemia.
  • Neurologic PET imaging, including assessment of epilepsy foci and dementia‑related metabolic patterns.
  • Whole‑body PET scans for staging of lymphoma and metastatic disease.
  • Research protocols investigating glucose metabolism in experimental models.

Side Effects

Adverse reactions to Gluco-Pet are generally mild and related to the radiopharmaceutical nature of the agent.

Common

  • Transient flushing or warmth at the injection site.
  • Mild nausea or headache.
  • Temporary metallic taste.
  • Short‑lasting dizziness.
  • Mild itching or rash.

Serious

  • Severe allergic reaction (anaphylaxis).
  • Prolonged hypotension.
  • Acute radiation syndrome (extremely rare, high‑dose exposure).
  • Persistent vomiting or severe abdominal pain.
  • Significant changes in blood glucose requiring medical intervention.

Precautions & Warnings

Specific precautions should be observed when using Gluco-Pet to ensure patient safety and optimal image quality.

  • Verify patient fasting status and blood glucose level before administration.
  • Assess renal function, as impaired clearance may affect tracer distribution.
  • Consider alternative imaging for pregnant or breastfeeding women due to radiation exposure.
  • Review history of allergic reactions to radiopharmaceuticals or iodine‑based contrast agents.
  • Ensure proper shielding and radiation safety protocols for staff and family members.
  • Document and monitor any adverse events during and after the procedure.

Avoid Interactions

Certain medications and conditions can influence the distribution and effectiveness of Gluco-Pet.

Avoid

  • High‑dose glucose‑containing solutions immediately before the scan.
  • Radiopharmaceuticals with overlapping emission spectra that could confound image interpretation.

Use with caution

  • Insulin or oral hypoglycemics (may alter blood glucose and tracer uptake).
  • Metformin (risk of lactic acidosis in patients with renal impairment).
  • Corticosteroids (can affect metabolic activity of tissues).
  • Beta‑blockers (may modify cardiac uptake patterns).
  • Thyroid hormone therapy (potential impact on cerebral metabolism).

Frequently Asked Questions

Fludeoxyglucose (18F) is a glucose analog that enters cells via glucose transporters, is phosphorylated by hexokinase, and becomes trapped intracellularly, allowing PET scanners to detect areas of increased metabolic activity.

Gluco-Pet is used for oncologic tumor detection and staging, cardiac viability and ischemia assessment, and neurologic studies such as epilepsy focus localization and dementia‑related metabolic patterns.

The product is supplied as an injectable solution and is given by a single intravenous bolus injection under controlled radiopharmacy conditions.

Standard radiation safety protocols include using the lowest effective activity, shielding of staff, limiting time near the patient, and adhering to regulatory dose limits for diagnostic procedures.

Use in pregnancy or lactation is generally avoided because of fetal and infant radiation exposure; alternative imaging methods should be considered unless the diagnostic benefit outweighs the risk.

Patients are typically instructed to fast for at least 4–6 hours and to maintain blood glucose levels within a target range to ensure optimal tracer uptake.

Elevated blood glucose can compete with the tracer for cellular uptake, potentially reducing image contrast; therefore, glucose levels are measured and, if necessary, corrected before injection.

Common side effects include transient flushing, mild nausea, headache, a brief metallic taste, and occasional itching or rash at the injection site.

Insulin, oral hypoglycemics, and high‑dose glucose solutions should be managed according to the imaging protocol; metformin may need temporary discontinuation in patients with renal impairment.

Radiologists and nuclear medicine physicians analyze the distribution of tracer uptake, comparing it to normal patterns and correlating with clinical information to identify abnormal metabolic activity.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fludeoxyglucose (18f)

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT